Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?

Tekgunduz E., Kaya A. H., CİVRİZ BOZDAĞ S., Kocubaba E., Kayikci O., Namdaroglu S., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.54, sa.1, ss.30-34, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.transci.2016.01.009
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.30-34
  • Anahtar Kelimeler: Acute graft-versus-host disease, Defibrotide, Acute GVHD, Prophylaxis, VENOOCCLUSIVE DISEASE, CLINICAL-TRIALS, ACUTE GVHD, BLOOD
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

There is some preliminary evidence, that veno-occlusive disease prophylaxis with defibrotide (DF) may also have a role in decreasing risk of acute graft-versus-host disease (aGvHD) by preventing tissue damage. In this study, we aimed to investigate the role of DF prophylaxis on the development of aGvHD at D + 180. One hundred ninety-five consecutive adult patients receiving allogeneic HCT were retrospectively evaluated in 3 groups: no DF, DF/post-Ha (DF D +1 to D + 14) and DF/pre-HCT (DF for 14 days concurrently with conditioning). The total (p: 0.057) and grades III/IV (p: 0.051) aGvHD rates at D + 180 were 46.5%, 40%, 25.5% and 15.5%, 11.2%, 0% in patients on no DF, DF/post-HCT and DF/pre-HCT. DF may have a role in decreasing incidence and severity of aGvHD, especially if used concurrently with conditioning regimen. (c) 2016 Elsevier Ltd. All rights reserved.